25I-NBF

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Jilja (talk | contribs) at 17:02, 16 October 2017 (UK legality). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

25I-NBF
Clinical data
ATC code
  • none
Identifiers
  • 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-fluorophenyl)methyl]ethan-1-amine
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H19FINO2
Molar mass415.240 g/mol g·mol−1
3D model (JSmol)
  • COc1cc(I)c(OC)cc1CCNCc2ccccc2F
  • InChI=1S/C17H19FINO2/c1-21-16-10-15(19)17(22-2)9-12(16)7-8-20-11-13-5-3-4-6-14(13)18/h3-6,9-10,20H,7-8,11H2,1-2H3 checkY
  • Key:LPBKNBHMWRBPHT-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

25I-NBF (2C-I-NBF, NBF-2C-I, Cimbi-21) is a derivative of the phenethylamine hallucinogen 2C-I, which acts as a highly potent partial agonist for the human 5-HT2A receptor.[1][2] It has been studied in its 11C radiolabelled form as a potential ligand for mapping the distribution of 5-HT2A receptors in the brain, using positron emission tomography (PET).[3]

Legality

25I-NBF is illegal in Hungary,[4] Japan,[5] Latvia,[6] and Vermont.[7]

Sweden

The Riksdag added 25I-NBF to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of January 26, 2016, published by Medical Products Agency (MPA) in regulation HSLF-FS 2015:35 listed as 25I-NBF, and 2-(4-jodo-2,5-dimetoxifenyl)-N-(2-fluorobensyl)etanamin.[8]

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[9]

Analogues and derivatives

References

  1. ^ Braden, MR; Parrish, JC; Naylor, JC; Nichols, DE (2006). "Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists". Molecular Pharmacology. 70 (6): 1956–64. doi:10.1124/mol.106.028720. PMID 17000863.
  2. ^ Michael Robert Braden PhD. Towards a biophysical understanding of hallucinogen action. Purdue University 2007.
  3. ^ Ettrup, A.; Hansen, M.; Santini, M. A.; Paine, J.; Gillings, N.; Palner, M.; Lehel, S.; Herth, M. M.; Madsen, J.; Kristensen, J.; Begtrup, M.; Knudsen, G. M. (2010). "Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers". European Journal of Nuclear Medicine and Molecular Imaging. 38 (4): 681–93. doi:10.1007/s00259-010-1686-8. PMID 21174090. {{cite journal}}: Unknown parameter |displayauthors= ignored (|display-authors= suggested) (help)
  4. ^ A Magyarországon megjelent, a Kábítószer és Kábítószer-függőség Európai Megfigyelő Központjának Korai Jelzőrendszerébe (EMCDDA EWS) 2005 óta bejelentett ellenőrzött anyagok büntetőjogi vonatkozású besorolása
  5. ^ "指定薬物名称・構造式一覧(平成27年9月16日現在)" (PDF) (in Japanese). 厚生労働省. 16 September 2015. Retrieved 8 October 2015.
  6. ^ Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem
  7. ^ "Regulated Drugs Rule" (PDF). Vermont Department of Health. Retrieved 14 October 2015.
  8. ^ https://lakemedelsverket.se/upload/lvfs/HSLF-FS/HSLFS-FS_2015_35.pdf
  9. ^ "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Statutory Instruments 2014 No. 1106. www.legislation.gov.uk.
  10. ^ "Explore N-(2C-I)-Fentanyl | PiHKAL · info". isomerdesign.com.